Nah JJ, et al. Clin Exp Vaccine Res. 2015 Jul;4(2):130-136. http://dx.doi.org/10.7774/cevr.2015.4.2.130

Lee SH, et al. Clin Exp Vaccine Res. 2018 Jan;7(1):61-69. https://doi.org/10.7774/cevr.2018.7.1.61

Yang DK, et al. Clin Exp Vaccine Res. 2017 Jul;6(2):111-119. https://doi.org/10.7774/cevr.2017.6.2.111

Yang DK, et al. Clin Exp Vaccine Res. 2014 Jul;3(2):212-219. https://doi.org/10.7774/cevr.2014.3.2.212

Yang DK, et al. Clin Exp Vaccine Res. 2018 Jul;7(2):87-92. https://doi.org/10.7774/cevr.2018.7.2.87

Rabies is an important viral zoonosis that causes acute encephalitis and death in mammals. To date, several recombinant vaccines have been developed based on G protein, which is considered to be the main antigen, and these vaccines are used for rabies control in many countries. Most recombinant viruses expressing RABV G protein retain the G gene from attenuated RABV. Not enough is currently known about the protective effect against RABV of a combination of recombinant adenoviruses expressing the G and N proteins of pathogenic street RABV. We constructed a recombinant adenovirus (Ad-0910Gsped) expressing the signal peptide and ectodomain (sped) of G protein of the Korean street strain, and evaluated the immunological protection conferred by a single and combination of three kinds of recombinant adenoviruses (Ad-0910Gsped and Ad-0910G with or without Ad-0910 N) in mice. A combination of Ad-0910G and Ad-0910 N conferred improved immunity against intracranial challenge compared to single administration of Ad-0910G. The Ad-0910G virus, expressing the complete G protein, was more immunogenic than Ad-0910Gsped, which expressed a truncated G protein with the transmembrane and cytoplasmic domains removed. Additionally, oral vaccination using a combination of viruses led to complete protection. Our results suggest that this combination of viruses is a viable new intramuscular and oral vaccine candidate.